Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06718270RecruitingEarly Phase 1
Study of CT0596 for Relapsed or Refractory Myeloma
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07393282RecruitingPhase 3
Comparing two treatments for high-risk smoldering multiple myeloma
This trial tests a new drug called linvoseltamab against an existing treatment, daratumumab, for people with a high-risk form of smoldering multiple myeloma. The goal is to see which one works better to delay or prevent the disease from becoming active multiple myeloma.
Phoenix, ArizonaAges 18 years+ - NCT07101445RecruitingPhase 4
Comparing steroids to prevent reactions to motixafortide in multiple myeloma
This trial tests two different steroid medicines (methylprednisolone and dexamethasone) to see which works better at preventing side effects from motixafortide, a drug used to help collect stem cells for a stem cell transplant in people with multiple myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT06679829RecruitingPhase 2
Melphalan with or without siltuximab for multiple myeloma stem cell transplant
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
Basking Ridge, New JerseyAges 60 years+ - NCT06623630RecruitingPhase 1
Carvykti with special radiation and chemo for kidney patients
This trial tests adding total body radiation and a chemotherapy drug (cyclophosphamide) before the standard Carvykti cell therapy for multiple myeloma patients who have kidney problems. The goal is to see if this approach is safe and effective for people with reduced kidney function.
St Louis, MissouriAges 18 years+ - NCT05828511RecruitingPhase 1/Phase 2
Study drug for newly diagnosed myeloma before standard treatment
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
Los Angeles, CaliforniaAges 18 years+ - NCT05706766Recruiting
Exercise coaching before stem cell transplant for multiple myeloma
This trial studies whether a structured exercise program before an autologous (your own cells) stem cell transplant can improve health and fitness in people with multiple myeloma. The goal is to safely prepare your body for transplant, and the study includes fitness testing and ongoing exercise training.
Boston, MassachusettsAges 18 years+ - NCT05623020RecruitingPhase 3
New treatment for newly diagnosed transplant-ineligible myeloma
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
Jupiter, FloridaAges 18 years+ - NCT03562169RecruitingPhase 3
Ixazomib with your own stem cell transplant for relapsed myeloma
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
AberdeenAges 18 years+ - NCT07638683RecruitingPhase 2
Teclistamab and Daratumumab for New Multiple Myeloma With Amyloidosis
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
ShanghaiAges 18 years+ - NCT06630104Recruiting
Studying blood cell changes after CAR-T therapy for blood cancers
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Scottsdale, ArizonaAges 18 years+ - NCT05640843Recruiting
Plant-based diet study for MGUS or smoldering myeloma
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
Atlanta, GeorgiaAges 18 years+ - NCT05405387RecruitingPhase 2
Budesonide to prevent serious diarrhea after stem cell transplant
This Phase 2 study tests whether budesonide can lower the chance of moderate-to-severe diarrhea in people with multiple myeloma who are getting an autologous stem cell transplant. It may help your comfort and reduce complications during the transplant recovery period.
Salt Lake City, UtahAges 18 years+ - NCT06463717Recruiting
Stem cell transplant timing for multiple myeloma with no cancer cells left
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Hangzhou, ZhejiangAges 18–70 - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+ - NCT05686447Recruiting
Testing blood samples to study multiple myeloma
This study looks at stored blood (serum) samples to see whether a lab test called MALDI-TOF mass spectrometry can help analyze multiple myeloma proteins. If you have multiple myeloma (or are a healthy matched control), your existing lab samples may be used for testing.
Guangzhou, GuangdongAges Any age - NCT05714839RecruitingPhase 1/Phase 2
Belantamab for multiple myeloma
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
Bullhead City, ArizonaAges 18 years+ - NCT05192122RecruitingPhase 1
Stop maintenance medicine in multiple myeloma with low remaining disease
This early-phase study looks at whether it’s safe to stop the usual “maintenance” medicine after a strong response in multiple myeloma. It aims to see if stopping treatment for people with very low remaining disease reduces drug exposure without allowing relapse too soon.
Chicago, IllinoisAges 18 years+ - NCT06789003Recruiting
Prehabilitation with exercise for multiple myeloma patients
This trial tests whether a prehabilitation program using adapted physical activity can help multiple myeloma patients prepare for a stem cell transplant. It may improve your strength and recovery before and after the transplant.
AvignonAges 18 years+ - NCT06066346RecruitingPhase 2
Talquetamab for multiple myeloma after CAR T-cell therapy
This study tests a drug called talquetamab for people with multiple myeloma who have already had a type of immunotherapy called CAR T-cell therapy (ide-cel). The goal is to see if talquetamab can help control the cancer after the CAR T cells have had time to work.
Basking Ridge, New JerseyAges 18 years+ - NCT06052826RecruitingPhase 2
Geriatric support to speed recovery after CAR-T for older adults
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
Duarte, CaliforniaAges 60 years+ - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
La Jolla, CaliforniaAges 18 years+ - NCT03689595Enrolling by invitation
PROMISE study: Predicting myeloma risk in high-risk groups
This study uses a blood test to find early signs of myeloma in people at higher risk, such as those with a family history or African ancestry. It aims to predict who might develop myeloma before symptoms appear.
Boston, MassachusettsAges 30 years+ - NCT06409702RecruitingPhase 4
Treating high-risk multiple myeloma with MRD testing
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
Suzhou, JiangsuAges 18 years+
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 540 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.